ACLY
ATP-citrate synthase
Also known as: ACL, ACLY_HUMAN, ATPCL, CLATP
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P53396
- Gene
- ACLY
- Ensembl
- ENSG00000131473
- Chromosome
- 17
- Canonical length
- 1101 aa
- Protein class
- Cancer-related genes, Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Primary cilium transition zone,Basal body,Cytosol,Principal piece
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
ATP citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. The enzyme is a tetramer (relative molecular weight approximately 440,000) of apparently identical subunits. It catalyzes the formation of acetyl-CoA and oxaloacetate from citrate and CoA with a concomitant hydrolysis of ATP to ADP and phosphate. The product, acetyl-CoA, serves several important biosynthetic pathways, including lipogenesis and cholesterogenesis. In nervous tissue, ATP citrate-lyase may be involved in the biosynthesis of acetylcholine. Multiple transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Dec 2014]
Canonical amino-acid sequenceUniProt
1101 residues, UniProt reviewed canonical sequence.
>P53396|ACLY
1 MSAKAISEQT GKELLYKFIC TTSAIQNRFK YARVTPDTDW ARLLQDHPWL LSQNLVVKPD
61 QLIKRRGKLG LVGVNLTLDG VKSWLKPRLG QEATVGKATG FLKNFLIEPF VPHSQAEEFY
121 VCIYATREGD YVLFHHEGGV DVGDVDAKAQ KLLVGVDEKL NPEDIKKHLL VHAPEDKKEI
181 LASFISGLFN FYEDLYFTYL EINPLVVTKD GVYVLDLAAK VDATADYICK VKWGDIEFPP
241 PFGREAYPEE AYIADLDAKS GASLKLTLLN PKGRIWTMVA GGGASVVYSD TICDLGGVNE
301 LANYGEYSGA PSEQQTYDYA KTILSLMTRE KHPDGKILII GGSIANFTNV AATFKGIVRA
361 IRDYQGPLKE HEVTIFVRRG GPNYQEGLRV MGEVGKTTGI PIHVFGTETH MTAIVGMALG
421 HRPIPNQPPT AAHTANFLLN ASGSTSTPAP SRTASFSESR ADEVAPAKKA KPAMPQDSVP
481 SPRSLQGKST TLFSRHTKAI VWGMQTRAVQ GMLDFDYVCS RDEPSVAAMV YPFTGDHKQK
541 FYWGHKEILI PVFKNMADAM RKHPEVDVLI NFASLRSAYD STMETMNYAQ IRTIAIIAEG
601 IPEALTRKLI KKADQKGVTI IGPATVGGIK PGCFKIGNTG GMLDNILASK LYRPGSVAYV
661 SRSGGMSNEL NNIISRTTDG VYEGVAIGGD RYPGSTFMDH VLRYQDTPGV KMIVVLGEIG
721 GTEEYKICRG IKEGRLTKPI VCWCIGTCAT MFSSEVQFGH AGACANQASE TAVAKNQALK
781 EAGVFVPRSF DELGEIIQSV YEDLVANGVI VPAQEVPPPT VPMDYSWARE LGLIRKPASF
841 MTSICDERGQ ELIYAGMPIT EVFKEEMGIG GVLGLLWFQK RLPKYSCQFI EMCLMVTADH
901 GPAVSGAHNT IICARAGKDL VSSLTSGLLT IGDRFGGALD AAAKMFSKAF DSGIIPMEFV
961 NKMKKEGKLI MGIGHRVKSI NNPDMRVQIL KDYVRQHFPA TPLLDYALEV EKITTSKKPN
1021 LILNVDGLIG VAFVDMLRNC GSFTREEADE YIDIGALNGI FVLGRSMGFI GHYLDQKRLK
1081 QGLYRHPWDD ISYVLPEHMS MLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ACLY can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 65 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 65 nTPM
- prostate: 59 nTPM
- duodenum: 47 nTPM
- thymus: 45 nTPM
- breast: 45 nTPM
- kidney: 44 nTPM
Single-cell type
- pancreatic islet cells: 201 nCPM
- prostatic glandular cells: 144 nCPM
- breast lactating cells: 110 nCPM
- gastric progenitor cells: 106 nCPM
- early spermatids: 98 nCPM
- alveolar cells type 2: 93 nCPM
Immune cell
- non-classical monocyte: 40 nTPM
- eosinophil: 37 nTPM
- T-reg: 34 nTPM
- total PBMC: 34 nTPM
- myeloid DC: 33 nTPM
- basophil: 32 nTPM
Brain region
- medulla oblongata: 185 nTPM
- pons: 179 nTPM
- cerebral cortex: 172 nTPM
- hypothalamus: 156 nTPM
- midbrain: 119 nTPM
- white matter: 107 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.38
- gnomAD pLI
- 0.08
- gnomAD missense Z
- 3.28
- DepMap mean gene effect
- -0.4
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- acetyl-CoA biosynthetic process
- cholesterol biosynthetic process
- citrate metabolic process
- coenzyme A metabolic process
- fatty acid biosynthetic process
- lipid biosynthetic process
- negative regulation of ferroptosis
- oxaloacetate metabolic process
Molecular functions
- ATP binding
- metal ion binding
- ATP citrate synthase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Citrate synthase
- CoA-binding
- ATP-citrate synthase/succinyl-CoA ligase, C-terminal domain
- Succinyl-CoA synthetase-like
- Citrate synthase-like, small alpha subdomain
- ATP-citrate lyase/succinyl-CoA ligase, active site
- Succinyl-CoA synthetase, beta subunit, conserved site
- ATP-citrate lyase/succinyl-CoA ligase, conserved site
- NAD(P)-binding domain superfamily
- Citrate synthase superfamily
- Citrate synthase, C-terminal domain
- CoA-ligase
- CoA binding domain
- ATP-citrate synthase
- ATP-citrate synthase, citrate-binding domain
- ATP-citrate synthase, ATP-grasp domain
- ATP citrate lyase citrate-binding
- ATP-citrate synthase ATP-grasp domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ACLY in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ACLY as an antibody target. Whether an autoantibody or antibody against ACLY could matter depends on whether native ACLY is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ACLY is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ACLY as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...